MAM
Martingale Asset Management Portfolio holdings
AUM
$4.08B
1-Year Return
20.69%
This Quarter Return
+2.24%
1 Year Return
+20.69%
3 Year Return
+65.38%
5 Year Return
+128.32%
10 Year Return
+323.81%
AUM
$5.19B
AUM Growth
+$56.7M
(+1.1%)
Cap. Flow
-$7.64M
Cap. Flow
% of AUM
-0.15%
Top 10 Holdings %
Top 10 Hldgs %
12.17%
Holding
912
New
89
Increased
357
Reduced
289
Closed
97
Top Buys
| 1 |
Darden Restaurants
DRI
|
$25.6M |
| 2 |
Chevron
CVX
|
$25M |
| 3 |
American Express
AXP
|
$21M |
| 4 |
Northrop Grumman
NOC
|
$19.2M |
| 5 |
Curtiss-Wright
CW
|
$14.6M |
Top Sells
| 1 |
Apple
AAPL
|
$25.2M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
$23.2M |
| 3 |
Mid-America Apartment Communities
MAA
|
$16.9M |
| 4 |
Old Dominion Freight Line
ODFL
|
$15.5M |
| 5 |
United Parcel Service
UPS
|
$15.3M |
Sector Composition
| 1 | Healthcare | 20.64% |
| 2 | Technology | 17.73% |
| 3 | Financials | 15.36% |
| 4 | Consumer Staples | 12.78% |
| 5 | Industrials | 11.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
776
Synchrony
SYF
$28B
| $207K | ﹤0.01% |
+7,122
| New | +$207K |
|
777
NVIDIA
NVDA
$4.04T
| $207K | ﹤0.01% |
+7,450
| New | +$207K |
|
|
MFA
778
MFA Financial
MFA
$1.07B
| $205K | ﹤0.01% |
+20,636
| New | +$205K |
|
779
Quest Diagnostics
DGX
$20.3B
| $202K | ﹤0.01% |
+1,426
| New | +$202K |
|
780
ALX Oncology
ALXO
$66.4M
| $202K | ﹤0.01% |
44,609
| – | – |
|
781
MiMedx Group
MDXG
$1.06B
| $201K | ﹤0.01% |
58,900
| – | – |
|
782
Valhi
VHI
$447M
| $195K | ﹤0.01% |
11,229
+1
| +0% | +$17 |
|
783
Acadia Pharmaceuticals
ACAD
$4.24B
| $195K | ﹤0.01% |
10,372
-2
| -0% | -$38 |
|
|
TVRD
784
Tvardi Therapeutics, Inc. Common Stock
TVRD
$287M
| $192K | ﹤0.01% |
1,084
| – | – |
|
|
AFCG
785
AFC Gamma
AFCG
$102M
| $191K | ﹤0.01% |
22,989
+1,330
| +6% | +$11.1K |
|
786
Aura Biosciences
AURA
$399M
| $189K | ﹤0.01% |
+20,354
| New | +$189K |
|
787
eGain
EGAN
$170M
| $189K | ﹤0.01% |
24,871
+6
| +0% | +$46 |
|
788
Sana Biotechnology
SANA
$739M
| $186K | ﹤0.01% |
56,915
| – | – |
|
789
N-able
NABL
$1.47B
| $173K | ﹤0.01% |
13,100
-29,447
| -69% | -$389K |
|
790
Century Therapeutics
IPSC
$43.2M
| $171K | ﹤0.01% |
+49,151
| New | +$171K |
|
791
Recursion Pharmaceuticals
RXRX
$2B
| $169K | ﹤0.01% |
25,400
+200
| +0.8% | +$1.33K |
|
792
CoreCivic
CXW
$2.1B
| $167K | ﹤0.01% |
+18,200
| New | +$167K |
|
793
Quad
QUAD
$339M
| $154K | ﹤0.01% |
+35,867
| New | +$154K |
|
794
Editas Medicine
EDIT
$235M
| $148K | ﹤0.01% |
20,420
+4,102
| +25% | +$29.7K |
|
795
Global Water Resources
GWRS
$266M
| $142K | ﹤0.01% |
11,411
| – | – |
|
796
Colony Bankcorp
CBAN
$300M
| $137K | ﹤0.01% |
13,415
+1,200
| +10% | +$12.2K |
|
|
KNTE
797
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $136K | ﹤0.01% |
21,822
-700
| -3% | -$4.38K |
|
798
Atea Pharmaceuticals
AVIR
$264M
| $134K | ﹤0.01% |
40,100
-176,185
| -81% | -$590K |
|
799
Heritage Commerce
HTBK
$629M
| $133K | ﹤0.01% |
+15,945
| New | +$133K |
|
800
C4 Therapeutics
CCCC
$201M
| $124K | ﹤0.01% |
39,420
+6,724
| +21% | +$21.1K |
|